Home > News  > OxOnc Study: positive results using AmoyDx ROS1 gene fusions test

OxOnc Study: positive results using AmoyDx ROS1 gene fusions test

Presented at ASCO 2016 the outcomes of the OxOnc Study in which the test has properly supported the completion of a Phase 2 study of crizotinib in patients with ROS1-Positive Non-Small Cell Lung Cancer

 

The OxOnc Study met its primary objective of demonstrating a high overall response rate for crizotinib. It enrolled 127 ROS1-positive patients in the People’s Republic of China (PRC), Japan, Taiwan and South Korea by using AmoyDx® ROS1 gene fusions test, and is the largest ROS1-positive NSCLC cohort reported to date. Results from the OxOnc Study were presented at the recent 2016 American Society of Clinical Oncology (ASCO) Annual Meeting.

 

For more information

Continue

This website uses cookies to deliver its services as described in our Cookie Policy. By using this website, you agree to the use of cookies.